Skip to main content
MAIA
NYSE Life Sciences

MAIA Reports 88% Disease Control Rate in Expanded Phase 2 THIO-101 Lung Cancer Study

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.02
Mkt Cap
$62.368M
52W Low
$0.87
52W High
$3.19
52W Position info
17% above low
Off High info
68% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MAIA sits 17% above its 52-week low of $0.87.

Summary

Updated Phase 2 THIO-101 Part C data showed an 88% disease control rate (38 of 43 patients) in third-line NSCLC, consistent with earlier study parts, and MAIA said further data may support an accelerated approval filing.


Key Events · Product Development and Regulatory · MAIA

  • 88% Disease Control Rate in Part C

    Across Parts A, B and C of THIO-101, 38 of 43 efficacy-evaluable third-line NSCLC patients (88%) had stable disease or better as of October 01, 2026, versus 25%-35% reported for standard third-line chemotherapy.

  • Part C Enrollment Complete

    Enrollment in the Part C expansion is complete, with patients enrolled in Hungary, Poland, Turkey, Georgia, Romania, Taiwan and the United States.

  • Accelerated Approval Path Flagged

    Further data from THIO-101 Part C may support an accelerated approval filing with FDA, MAIA said; ateganosine holds Fast Track designation.

  • Phase 3 Readout Not Until 2027

    The pivotal Phase 3 THIO-104 trial in the same third-line population is advancing toward a 2027 interim survival analysis, leaving a multi-year gap before registrational data.


Analysis · MAIA · Life Sciences

The key takeaway is consistency: MAIA's lead asset ateganosine now shows efficacy across a much larger patient pool, with 38 of 43 third-line NSCLC patients (88%) achieving stable disease or better, versus 25%-35% typically reported for standard third-line chemotherapy. Parts A and B were small, and Part C was run specifically to confirm the signal in more patients, so this readout de-risks the program ahead of the pivotal Phase 3 THIO-104 trial. Management also flags that further Part C data may support an accelerated approval filing, which would shorten the path to market. The counterweight is timing and cash: the Phase 3 interim survival analysis is not expected until 2027, and the company is funding that wait from the $21.34M cash balance reported with its November 9 10-Q.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MAIA was trading at $1.02 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.4M. The 52-week trading range was $0.87 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MAIA - Latest Insights

MAIA
Nov 09, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $1.01 info
Change: -$0.080 (-7%) info
Market Cap: $62.368M info